Table 1 Reported outcomes and follow up periods.

From: Long-term (2–5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis

Trials

Reported outcomes

Follow up period

ENDEAVOR III16

Death, cardiac death, MI, definite/probable ST, TLR, TVR, MACEs

5 years

ENDEAVOR IV17

Death, cardiac death, MI, TLR, TVR, MACEs, definite/probable ST

5 years

ISAR TEST 218

Death, MI, MACEs, definite/probable ST

2 years

PRODIGY19

Death, MI, TVR, definite/probable ST, MACEs

2 years

PROTECT12

Death, cardiac death, MI, TLR, TVR, MACEs, definite/probable ST

4 years

SORT OUT III20

Death, cardiac death, MI, MACEs, TVR, TLR, definite ST

5 years

ZEST21

Death, cardiac death, MI, MACEs, TLR, TVR, definite or probable ST

2 years

PRISON III22

Death, cardiac death, MI, TVR, MACEs, definite or probable ST

3 years

ZOMAxx I23

Death, cardiac death, MI, TVR, TLR, MACEs, definite or probable ST

5 years

RESOLUTE24

Death, cardiac death, MI, TVR, TLR, MACEs, definite or probable ST

4 years

TWENTE25

Death, cardiac death, MI, TVR, TLR, MACEs, definite or probable ST

2 years

TWENTE II26

Death, cardiac death, MI, TVR, TLR, MACEs, definite or probable ST

2 years

  1. Abbreviations: ST: stent thrombosis, TLR: target lesion revascularization, TVR: target vessel revascularization, MACEs: major adverse cardiac events, MI: myocardial infarction.